Recipharm cites sales and earnings hike in acquisition plan

By Gareth Macdonald

- Last updated on GMT

Recipharm cites sales and earnings hike in acquisition plan
Recipharm AB will continue its spending spree of the past few years according to CEO Thomas Eldered, who reiterated the CMO’s plan to grow through takeovers in a results presentation earlier today.

The Swedish contract manufacturing organisation (CMO), which completed its initial public offering (IPO) on the NASDAQOMX in April​, saw net sales increase 15% to SEK611m (€89m) and profit after tax climb 40% to SEK74m.

Recipharm said that all of its business segments had reported improvements and described the progress made by its development and technology operations as “particularly good​.”

Despite only being a public company for four months, Recipharm has already spoken about its desire to growth through acquisitions several times.

Eldered reiterated this again today citing the firm’s financials.

These good results combined with the company’s strong balance sheet leave us very well positioned to boost this positive growth through profitable acquisitions and outsourcing transactions with major pharmaceutical companies.”

During the period we analyzed and evaluated a number of interesting potential acquisitions that could expand our customer base as well as providing geographical expansion and new technologies. We expect this to result in acquisition activities.”

Even before the IPO Recipharm was no slouch in the growth department. In the past five years, for example, the CDMO has completed multiple acquisitions​, numerous facility expansions​ and carve outs​.

However, recent consolidation in the services sector has further increased the pressure on CDMOs to offer both a diverse range of capabilities and global reach.

Recipharm told us earlier this year that: “Our asset base is still focused on Europe although we have customers worldwide. There are still areas of Europe where we believe we can still expand, but we are looking further afield.

An obvious choice is the US but there are also attractive opportunities in emerging markets which we will continue to evaluate​.”

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Products

View more

Webinars